Nucleotide Market Size, Share & Trends Analysis Report By Product (Deoxy Nucleotides), By Technology (TaqMan Allelic Discrimination, Gene Chips & Microarrays), By Application, By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,950	120 Pages	Grand View Research	February, 2025	GV19793442

Best Price Guarantee
Price	from $5,950
Length	120 Pages
Publisher	Grand View Research
Published Date	February, 2025
SKU	GV19793442

Table of Contents
Description

Nucleotide Market Growth & Trends

The global nucleotide market size is expected to reach USD 1.52 billion by 2030, registering a CAGR of 8.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global nucleotide market is expected to witness substantial growth over the forecast period owing to its widespread use in pharmaceuticals and food & beverage industries. Diagnostic research along with pharmaceutical applications dominated the nucleotide market owning to properties including enhanced immunity, positive effects on the intestines, and positive effects of recovery from stress. In addition, growing R&D in the field of dietary nucleotide coupled with yeast-derived nucleotide for livestock nutrition across the globe is expected to propel demand over the forecast period.

Nucleotide Market Report Highlights

The TaqMan allelic discrimination segment dominated the global market in 2024, followed by SNP by pyrosequencing
The diagnostics research segment dominated the global market for nucleotides in 2024
The deoxy nucleotides (dNTPs) segment dominated the global nucleotide market in 2024 with a revenue share of 48.4% and is furthermore likely to expand with the fastest CAGR over the forecast period
North America nucleotide market secured the largest market share of 38.9% in 2024 and Europe nucleotide market is set to expand at the fastest-growing CAGR of 8.4% from 2025 to 2030

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation & Scope; 1.2. Segment Definitions; 1.2.1. Product; 1.2.2. Technology; 1.2.3. Application; 1.3. Estimates and Forecast Timeline; 1.4. Research Methodology; 1.5. Information Procurement; 1.5.1. Purchased Database; 1.5.2. GVR’s Internal Database; 1.5.3. Secondary Sources; 1.5.4. Primary Research; 1.6. Information Analysis; 1.6.1. Data Analysis Models; 1.7. Market Formulation & Data Visualization; 1.8. Model Details; 1.8.1. Commodity Flow Analysis; 1.9. List of Secondary Sources; 1.10. Objectives
Chapter 2. Executive Summary: 2.1. Market Snapshot; 2.2. Segment Snapshot; 2.3. Competitive Landscape Snapshot
Chapter 3. Nucleotide Market Variables, Trends, & Scope: 3.1. Market Lineage Outlook; 3.2. Market Dynamics; 3.2.1. Market Driver Analysis; 3.2.2. Market Restraint Analysis; 3.3. Business Environment Analysis; 3.3.1. Industry Analysis - Porter’s Five Forces Analysis; 3.3.1.1. Supplier Power; 3.3.1.2. Buyer Power; 3.3.1.3. Substitution Threat; 3.3.1.4. Threat of New Entrant; 3.3.1.5. Competitive Rivalry; 3.3.2. PESTLE Analysis
Chapter 4. Nucleotide Market: Product Business Analysis: 4.1. Product Market Share, 2024 & 2030; 4.2. Product Segment Dashboard; 4.3. Market Size & Forecasts and Trend Analysis, By Product, 2018 to 2030 (USD Million); 4.4. Deoxy Nucleotides; 4.4.1. Deoxy Nucleotides Market, 2018 - 2030 (USD Million); 4.4.1.1. Enzyme Sourced; 4.4.1.1.1. Enzyme Sourced Nucleotides Market, 2018 - 2030 (USD Million); 4.4.1.2. Chemical Synthesis; 4.4.1.2.1. Chemical Synthesis Nucleotides Market, 2018 - 2030 (USD Million); 4.5. Dideoxynucleotides; 4.5.1. Dideoxynucleotides Market, 2018 - 2030 (USD Million); 4.6. Nucleotides for RNA Synthesis (rNTP); 4.6.1. Nucleotides for RNA Synthesis (rNTP) Market, 2018 - 2030 (USD Million); 4.7. Labelled Nucleotides; 4.7.1. Labelled Nucleotides Market, 2018 - 2030 (USD Million)
Chapter 5. Nucleotide Market: Technology Business Analysis: 5.1. Technology Market Share, 2024 & 2030; 5.2. Technology Segment Dashboard; 5.3. Market Size & Forecasts and Trend Analysis, By Technology, 2018 to 2030 (USD Million); 5.4. TaqMan Allelic Discrimination; 5.4.1. TaqMan Allelic Discrimination Market, 2018 - 2030 (USD Million); 5.5. Gene Chips & Microarrays; 5.5.1. Gene Chips & Microarrays Market, 2018 - 2030 (USD Million); 5.6. SNP by Pyrosequencing; 5.6.1. Gene Chips & Microarrays Market, 2018 - 2030 (USD Million); 5.7. Others; 5.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Nucleotide Market: Application Business Analysis: 6.1. Application Market Share, 2024 & 2030; 6.2. Application Segment Dashboard; 6.3. Market Size & Forecasts and Trend Analysis, By Application, 2018 to 2030 (USD Million); 6.4. Pharmaceuticals; 6.4.1. Pharmaceuticals Market, 2018 - 2030 (USD Million); 6.5. Diagnostics Research; 6.5.1. Diagnostics Research Market, 2018 - 2030 (USD Million); 6.6. Food & Beverage Additive; 6.6.1. Food & Beverage Additive Market, 2018 - 2030 (USD Million); 6.7. Animal Feed Additive; 6.7.1. Animal Feed Additive Market, 2018 - 2030 (USD Million); 6.8. Others; 6.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Nucleotide Market: Regional Estimates & Trend Analysis: 7.1. Regional Market Share Analysis, 2024 & 2030; 7.2. Regional Market Dashboard; 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:; 7.4. North America; 7.4.1. North America Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.4.2. U.S.; 7.4.2.1. Key Country Dynamic; 7.4.2.2. Regulatory Framework; 7.4.2.3. Competitive Insights; 7.4.2.4. U.S. Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.4.3. Canada; 7.4.3.1. Key Country Dynamic; 7.4.3.2. Regulatory Framework; 7.4.3.3. Competitive Insights; 7.4.3.4. Canada Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.4.4. Mexico; 7.4.4.1. Key Country Dynamic; 7.4.4.2. Regulatory Framework; 7.4.4.3. Competitive Insights; 7.4.4.4. Mexico Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5. Europe; 7.5.1. Europe Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.2. UK; 7.5.2.1. Key Country Dynamic; 7.5.2.2. Regulatory Framework; 7.5.2.3. Competitive Insights; 7.5.2.4. UK Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.3. Germany; 7.5.3.1. Key Country Dynamic; 7.5.3.2. Regulatory Framework; 7.5.3.3. Competitive Insights; 7.5.3.4. Germany Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.4. France; 7.5.4.1. Key Country Dynamic; 7.5.4.2. Regulatory Framework; 7.5.4.3. Competitive Insights; 7.5.4.4. France Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.5. Italy; 7.5.5.1. Key Country Dynamic; 7.5.5.2. Regulatory Framework; 7.5.5.3. Competitive Insights; 7.5.5.4. Italy Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.6. Spain; 7.5.6.1. Key Country Dynamic; 7.5.6.2. Regulatory Framework; 7.5.6.3. Competitive Insights; 7.5.6.4. Spain Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.7. Denmark; 7.5.7.1. Key Country Dynamic; 7.5.7.2. Regulatory Framework; 7.5.7.3. Competitive Insights; 7.5.7.4. Denmark Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.8. Sweden; 7.5.8.1. Key Country Dynamic; 7.5.8.2. Regulatory Framework; 7.5.8.3. Competitive Insights; 7.5.8.4. Sweden Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.5.9. Norway; 7.5.9.1. Key Country Dynamic; 7.5.9.2. Regulatory Framework; 7.5.9.3. Competitive Insights; 7.5.9.4. Norway Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.6. Asia Pacific; 7.6.1. Asia Pacific Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.6.2. Japan; 7.6.2.1. Key Country Dynamic; 7.6.2.2. Regulatory Framework; 7.6.2.3. Competitive Insights; 7.6.2.4. Japan Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.6.3. China; 7.6.3.1. Key Country Dynamic; 7.6.3.2. Regulatory Framework; 7.6.3.3. Competitive Insights; 7.6.3.4. China Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.6.4. India; 7.6.4.1. Key Country Dynamic; 7.6.4.2. Regulatory Framework; 7.6.4.3. Competitive Insights; 7.6.4.4. India Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.6.5. Australia; 7.6.5.1. Key Country Dynamic; 7.6.5.2. Regulatory Framework; 7.6.5.3. Competitive Insights; 7.6.5.4. Australia Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.6.6. Thailand; 7.6.6.1. Key Country Dynamic; 7.6.6.2. Regulatory Framework; 7.6.6.3. Competitive Insights; 7.6.6.4. Thailand Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.6.7. South Korea; 7.6.7.1. Key Country Dynamic; 7.6.7.2. Regulatory Framework; 7.6.7.3. Competitive Insights; 7.6.7.4. South Korea Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.7. Latin America; 7.7.1. Latin America Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.7.2. Brazil; 7.7.2.1. Key Country Dynamic; 7.7.2.2. Regulatory Framework; 7.7.2.3. Competitive Insights; 7.7.2.4. Brazil Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.7.3. Argentina; 7.7.3.1. Key Country Dynamic; 7.7.3.2. Regulatory Framework; 7.7.3.3. Competitive Insights; 7.7.3.4. Argentina Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.8. Middle East and Africa; 7.8.1. Middle East and Africa Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.8.2. South Africa; 7.8.2.1. Key Country Dynamic; 7.8.2.2. Regulatory Framework; 7.8.2.3. Competitive Insights; 7.8.2.4. South Africa Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.8.3. Saudi Arabia; 7.8.3.1. Key Country Dynamic; 7.8.3.2. Regulatory Framework; 7.8.3.3. Competitive Insights; 7.8.3.4. Saudi Arabia Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.8.4. UAE; 7.8.4.1. Key Country Dynamic; 7.8.4.2. Regulatory Framework; 7.8.4.3. Competitive Insights; 7.8.4.4. UAE Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million); 7.8.5. Kuwait; 7.8.5.1. Key Country Dynamic; 7.8.5.2. Regulatory Framework; 7.8.5.3. Competitive Insights; 7.8.5.4. Kuwait Nucleotide Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape: 8.1. Participant Overview; 8.2. Company Market Position Analysis; 8.3. Company Categorization; 8.4. Strategy Mapping; 8.5. Company Profiles/Listing; 8.5.1. CJ CheilJedang Corp.; 8.5.1.1. Participant’s Overview; 8.5.1.2. Financial Performance; 8.5.1.3. Product Benchmarking; 8.5.1.4. Strategic Initiatives; 8.5.2. Star Lake Bioscience; 8.5.2.1. Participant’s Overview; 8.5.2.2. Financial Performance; 8.5.2.3. Product Benchmarking; 8.5.2.4. Strategic Initiatives; 8.5.3. Thermo Fisher Scientific Inc.; 8.5.3.1. Participant’s Overview; 8.5.3.2. Financial Performance; 8.5.3.3. Product Benchmarking; 8.5.3.4. Strategic Initiatives; 8.5.4. MEIHUA HOLDINGS GROUP CO., LTD.; 8.5.4.1. Participant’s overview; 8.5.4.2. Financial Performance; 8.5.4.3. Product Benchmarking; 8.5.4.4. Strategic Initiatives; 8.5.5. F. Hoffmann-La Roche Ltd.; 8.5.5.1. Participant’s Overview; 8.5.5.2. Financial Performance; 8.5.5.3. Product Benchmarking; 8.5.5.4. Strategic Initiatives; 8.5.6. Biorigin; 8.5.6.1. Participant’s Overview; 8.5.6.2. Financial Performance; 8.5.6.3. Product Benchmarking; 8.5.6.4. Strategic Initiatives; 8.5.7. DSM; 8.5.7.1. Participant’s Overview; 8.5.7.2. Financial Performance; 8.5.7.3. Product Benchmarking; 8.5.7.4. Strategic Initiatives; 8.5.8. Promega Corporation; 8.5.8.1. Participant’s Overview; 8.5.8.2. Financial Performance; 8.5.8.3. Product Benchmarking; 8.5.8.4. Strategic Initiatives; 8.5.9. Agilent Technologies, Inc.; 8.5.9.1. Participant’s Overview; 8.5.9.2. Financial Performance; 8.5.9.3. Product Benchmarking; 8.5.9.4. Strategic Initiatives; 8.5.10. Lallemand Inc.; 8.5.10.1. Participant’s Overview; 8.5.10.2. Financial Performance; 8.5.10.3. Product Benchmarking; 8.5.10.4. Strategic Initiatives; 8.5.11. Nanjing Biotogether Co., Ltd.; 8.5.11.1. Participant’s Overview; 8.5.11.2. Financial Performance; 8.5.11.3. Product Benchmarking; 8.5.11.4. Strategic Initiatives; 8.5.12. NuEra Nutraceuticals Inc.; 8.5.12.1. Participant’s Overview; 8.5.12.2. Financial Performance; 8.5.12.3. Product Benchmarking; 8.5.12.4. Strategic Initiatives; 8.5.13. Ohly; 8.5.13.1. Participant’s Overview; 8.5.13.2. Financial Performance; 8.5.13.3. Product Benchmarking; 8.5.13.4. Strategic Initiatives